MASLD Metabolic Risk Explorer & Educational Visualizer

01 Biomarker Modeler

Preset: Standard

Clinical Presets

Waist Circumference 94 cm

65 cmMale >94cm / Fem >80cm140 cm

Body Mass Index (BMI) 27.5 kg/m²

18.5 Normal25 Overweight30+ Obese

Fasting Blood Glucose 105 mg/dL

70 Normal100 Pre-Diabetic126+ T2D

Triglycerides 185 mg/dL

<150 Normal150-199 Borderline>200 High

HDL Cholesterol 42 mg/dL

<40 Low (Male)<50 Low (Fem)>60 Protective

ALT / AST Enzymes 38 / 32 U/L

Normal <30 U/LElevated Inflammation

Weekly Activity 60 min/wk

0 Sedentary150 Target300 High

02 Histology & Pathway Visualizer

Simple Steatosis

Dynamic Liver Histology (Microscopic Cross-Section)

Fat Accumulation: 24% of Hepatocytes

Healthy Hepatocyte

Lipid Macrovesicle

Inflammatory Infiltrate

Collagen Fibrosis Fiber

Metabolic Feedback Cascade (Path to Diabetes & CVD) Flux Level: Moderate

Pathophysiology Insight: Intrahepatic lipid storage (triglyceride buildup) triggers diacylglycerol release, inhibiting hepatic insulin signaling. This promotes continuous gluconeogenesis and hyperinsulinemia, accelerating systemic vascular inflammation.

03 Outcomes & Risk Trajectory

MASLD / Hepatic Steatosis Risk Moderate Risk

64%

Probability of intrahepatic fat > 5%

FIB-4 Fibrosis Risk Category Low Fibrosis Risk

1.12

Cutoffs: <1.30 Low | >2.67 High

Cardiometabolic Risk Score Elevated

3.8x

Increased risk of T2D & Atherosclerosis

High triglycerides and insulin resistance double 10-year major adverse cardiovascular event (MACE) rates.

Lifestyle Weight Reduction Impact

Target Weight Loss 7% Reduction

Liver Fat Reduction

-42%

Fasting Glucose Impact

-14 mg/dL

ALT Enzyme Drop

-18 U/L

NASH Resolution Rate

65%